Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysis
BackgroundJin Shui Liu Jun Decoction (JLD) is a classical prescription in Traditional Chinese Medicine (TCM). In recent years, JLD has shown beneficial effects on patients with chronic obstructive pulmonary disease (COPD). However, the existing clinical research results are contradictory, and high-q...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1567452/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849228955349942272 |
|---|---|
| author | Wanqiu Huang Hui Wang Di Wu Lu Zhang Jiabing Tong Jiabing Tong Minghui Yu Zegeng Li Zegeng Li Qinjun Yang Qinjun Yang |
| author_facet | Wanqiu Huang Hui Wang Di Wu Lu Zhang Jiabing Tong Jiabing Tong Minghui Yu Zegeng Li Zegeng Li Qinjun Yang Qinjun Yang |
| author_sort | Wanqiu Huang |
| collection | DOAJ |
| description | BackgroundJin Shui Liu Jun Decoction (JLD) is a classical prescription in Traditional Chinese Medicine (TCM). In recent years, JLD has shown beneficial effects on patients with chronic obstructive pulmonary disease (COPD). However, the existing clinical research results are contradictory, and high-quality, evidence-based medical evidence is lacking. Therefore, the exact therapeutic efficacy of JLD has not been fully evaluated.ObjectivesThis study aimed to ascertain the precise therapeutic efficacy of JLD in treating COPD.Data sources and MethodA search of 10 electronic databases was conducted up to 30 November 2024. The standardized mean difference (SMD) was used to assess continuous variables, while the relative risk (RR) was calculated to evaluate dichotomous variables. The Luis Furuya-Kanamori (LFK) asymmetry index, along with the Doi plot, Egger’s test, and Begg’s test, were used to assess publication bias. Sensitivity analysis was performed to evaluate the stability of the conclusions. Furthermore, trial sequential analysis (TSA) was used to assess the risk of false-positive results and to estimate the required sample size for the meta-analysis. Finally, single-factor and multi-factor meta-regression were conducted to analyze the sources of heterogeneity.ResultsA total of 22 trials meeting the inclusion criteria were included, including 1,817 COPD participants. The meta-analysis indicated that JLD could improve overall treatment efficacy (RR = 1.15, 95% CI: 1.053–1.256, PZ = 0.002) and pulmonary function (FEV1: SMD = 0.661, 95% CI: 0.276–1.046, PZ = 0.001; FEV1% Predicted: SMD = 0.368, 95% CI: 0.067–0.669, PZ = 0.017; FVC: SMD = 0.814, 95% CI: 0.392–1.235, PZ < 0.001; FEV1/FVC Ratio: SMD = 0.602, 95% CI: 0.311–0.893, PZ < 0.001) in COPD, potentially offering benefits in traditional Chinese medicine syndrome scores (SMD = 0.936, 95% CI: 0.301–1.571, PZ = 0.004) and 6-min walk distance (6MWD: SMD = 0.744, 95% CI: 0.182–1.306, PZ = 0.009). The subgroup analysis revealed a higher overall efficacy and improvement in FEV1/FVC Ratio of JLD treatment for stable chronic obstructive pulmonary disease (sCOPD) compared to the acute exacerbation of chronic obstructive pulmonary disease (AECOPD) group (SMD:0.605 v.s. 0.574, PZ < 0.05). Additionally, compared to the simple JLD treatment plan, the conventional biomedicine (CBM)+JLD scheme showed superior overall efficacy in treating COPD patients (RR = 1.15, 95% CI: 1.043–1.268, PZ = 0.005).ConclusionTreatment with JLD can effectively improve the overall efficacy and pulmonary function (FEV1%pred requires more research for confirmation) of COPD patients. However, the methodological quality of the included trials may limit the generalizability of the study’s findings. Sources of heterogeneity were partially identified through meta-regression, but further rigorous randomized controlled trials are still required.Systematic Review Registrationhttps://osf.io/msw7b. |
| format | Article |
| id | doaj-art-b03cff50b04948499b413e5353d402b7 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-b03cff50b04948499b413e5353d402b72025-08-22T11:54:22ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-05-011610.3389/fphar.2025.15674521567452Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysisWanqiu Huang0Hui Wang1Di Wu2Lu Zhang3Jiabing Tong4Jiabing Tong5Minghui Yu6Zegeng Li7Zegeng Li8Qinjun Yang9Qinjun Yang10Anhui University of Chinese Medicine, Hefei, ChinaAnhui University of Chinese Medicine, Hefei, ChinaThe First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, ChinaAnhui University of Chinese Medicine, Hefei, ChinaAnhui Province Key Laboratory of the Application and Transformation of Traditional Chinese Medicine in the Prevention and Treatment of Major Pulmonary Diseases, Hefei, ChinaThe First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, ChinaThe First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, ChinaAnhui Province Key Laboratory of the Application and Transformation of Traditional Chinese Medicine in the Prevention and Treatment of Major Pulmonary Diseases, Hefei, ChinaThe First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, ChinaAnhui University of Chinese Medicine, Hefei, ChinaAnhui Province Key Laboratory of the Application and Transformation of Traditional Chinese Medicine in the Prevention and Treatment of Major Pulmonary Diseases, Hefei, ChinaBackgroundJin Shui Liu Jun Decoction (JLD) is a classical prescription in Traditional Chinese Medicine (TCM). In recent years, JLD has shown beneficial effects on patients with chronic obstructive pulmonary disease (COPD). However, the existing clinical research results are contradictory, and high-quality, evidence-based medical evidence is lacking. Therefore, the exact therapeutic efficacy of JLD has not been fully evaluated.ObjectivesThis study aimed to ascertain the precise therapeutic efficacy of JLD in treating COPD.Data sources and MethodA search of 10 electronic databases was conducted up to 30 November 2024. The standardized mean difference (SMD) was used to assess continuous variables, while the relative risk (RR) was calculated to evaluate dichotomous variables. The Luis Furuya-Kanamori (LFK) asymmetry index, along with the Doi plot, Egger’s test, and Begg’s test, were used to assess publication bias. Sensitivity analysis was performed to evaluate the stability of the conclusions. Furthermore, trial sequential analysis (TSA) was used to assess the risk of false-positive results and to estimate the required sample size for the meta-analysis. Finally, single-factor and multi-factor meta-regression were conducted to analyze the sources of heterogeneity.ResultsA total of 22 trials meeting the inclusion criteria were included, including 1,817 COPD participants. The meta-analysis indicated that JLD could improve overall treatment efficacy (RR = 1.15, 95% CI: 1.053–1.256, PZ = 0.002) and pulmonary function (FEV1: SMD = 0.661, 95% CI: 0.276–1.046, PZ = 0.001; FEV1% Predicted: SMD = 0.368, 95% CI: 0.067–0.669, PZ = 0.017; FVC: SMD = 0.814, 95% CI: 0.392–1.235, PZ < 0.001; FEV1/FVC Ratio: SMD = 0.602, 95% CI: 0.311–0.893, PZ < 0.001) in COPD, potentially offering benefits in traditional Chinese medicine syndrome scores (SMD = 0.936, 95% CI: 0.301–1.571, PZ = 0.004) and 6-min walk distance (6MWD: SMD = 0.744, 95% CI: 0.182–1.306, PZ = 0.009). The subgroup analysis revealed a higher overall efficacy and improvement in FEV1/FVC Ratio of JLD treatment for stable chronic obstructive pulmonary disease (sCOPD) compared to the acute exacerbation of chronic obstructive pulmonary disease (AECOPD) group (SMD:0.605 v.s. 0.574, PZ < 0.05). Additionally, compared to the simple JLD treatment plan, the conventional biomedicine (CBM)+JLD scheme showed superior overall efficacy in treating COPD patients (RR = 1.15, 95% CI: 1.043–1.268, PZ = 0.005).ConclusionTreatment with JLD can effectively improve the overall efficacy and pulmonary function (FEV1%pred requires more research for confirmation) of COPD patients. However, the methodological quality of the included trials may limit the generalizability of the study’s findings. Sources of heterogeneity were partially identified through meta-regression, but further rigorous randomized controlled trials are still required.Systematic Review Registrationhttps://osf.io/msw7b.https://www.frontiersin.org/articles/10.3389/fphar.2025.1567452/fullJinshui Liujun decoctiontraditional Chinese medicinechronic obstructive pulmonary diseasetrial sequential analysismeta-analysis |
| spellingShingle | Wanqiu Huang Hui Wang Di Wu Lu Zhang Jiabing Tong Jiabing Tong Minghui Yu Zegeng Li Zegeng Li Qinjun Yang Qinjun Yang Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysis Frontiers in Pharmacology Jinshui Liujun decoction traditional Chinese medicine chronic obstructive pulmonary disease trial sequential analysis meta-analysis |
| title | Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysis |
| title_full | Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysis |
| title_fullStr | Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysis |
| title_short | Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysis |
| title_sort | efficacy of jinshui liujun decoction on chronic obstructive pulmonary disease patients a systematic review and meta analysis |
| topic | Jinshui Liujun decoction traditional Chinese medicine chronic obstructive pulmonary disease trial sequential analysis meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1567452/full |
| work_keys_str_mv | AT wanqiuhuang efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT huiwang efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT diwu efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT luzhang efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT jiabingtong efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT jiabingtong efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT minghuiyu efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT zegengli efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT zegengli efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT qinjunyang efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT qinjunyang efficacyofjinshuiliujundecoctiononchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis |